Is Wall Street Bullish or Bearish on Waters Corporation Stock?
Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.
How this was made
%252FWaters%252520Corporation%252520on%252520the%252520screen%252520of%252520an%252520exchange_By%252520maurice%252520norbert.jpeg&w=3840&q=75)
The 30-second read
Why it matters
The earnings beat and raised guidance suggest continued revenue momentum, likely prompting analysts to lift price targets.
Market read
Waters' strong Q2 results and upgraded outlook provide a bullish catalyst for the broader health‑care equipment sector.
What to watch
Potential supply‑chain constraints or slower adoption of new biosciences acquisitions could limit growth.
Background
Waters Corporation is a $40.7 B lab‑equipment and diagnostics provider with a 16,000‑employee base.
Ticker impact
Waters reported Q2 2026 earnings beat and raised FY guidance, causing a 5.7% price jump on Aug. 4.
Potential 8‑12% upside over the next few weeks if guidance holds.
Quarterly beat, double‑digit revenue growth, and upgraded price target indicate bullish momentum.
Market effects
Positive for the life‑sciences instrumentation sector as demand remains robust.
Supports broader health‑care and biotech sentiment in the U.S. market.
Reinforces confidence in global lab‑equipment suppliers amid ongoing R&D spending.
Counterpoint
If guidance falls short of market expectations later in the year, the stock could face a correction.
Key entities
- AnalystBarclays
Raised price target to $460 and kept an Overweight rating.
